Want to join the conversation?
$KR said that for FY16 it expects net earnings in the range of $2.19-2.28 per diluted share and expects its core business to grow in line with its long-term net diluted EPS growth rate of 8-11%. The company also expects capital investments, excluding mergers, acquisitions and purchases of leased facilities, to be in the $4.1-4.4Bil range for 2016.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.